tiprankstipranks
Alnylam Pharmaceuticals (CH:DUL)
NASDAQ:DUL
Switzerland Market
DUL
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (DUL) Financial Statements

0 Followers

Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently CHF31.10B. The company's EPS TTM is CHF4.36; its P/E ratio is 67.26; Alnylam Pharma is scheduled to report earnings on April 30, 2026, and the estimated EPS forecast is CHF1.27. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 3.71B$ 2.25B$ 1.83B$ 1.04B$ 844.29M
Gross Profit$ 3.04B$ 1.92B$ 1.52B$ 868.60M$ 704.14M
Operating Income$ 501.58M$ -176.88M$ -282.18M$ -785.07M$ -708.65M
EBITDA$ 557.24M$ -178.85M$ -258.24M$ -926.56M$ -661.56M
Net Income$ 313.75M$ -278.16M$ -440.24M$ -1.13B$ -852.82M
Balance Sheet
Cash & Short-Term Investments$ 2.91B$ 2.69B$ 2.44B$ 2.19B$ 2.44B
Total Assets$ 4.97B$ 4.24B$ 3.83B$ 3.55B$ 3.64B
Total Debt$ 1.28B$ 2.74B$ 1.31B$ 1.32B$ 997.59M
Net Debt$ -378.86M$ 1.78B$ 492.70M$ 453.85M$ 177.62M
Total Liabilities$ 4.18B$ 4.17B$ 4.05B$ 3.70B$ 3.06B
Stockholders' Equity$ 789.18M$ 67.09M$ -220.64M$ -158.22M$ 588.20M
Cash Flow
Free Cash Flow$ 465.38M$ -42.59M$ 41.95M$ -613.33M$ -718.07M
Operating Cash Flow$ 524.08M$ -8.31M$ 104.16M$ -541.27M$ -641.69M
Investing Cash Flow$ 436.33M$ -116.84M$ -336.35M$ 169.35M$ -273.30M
Financing Cash Flow$ -305.19M$ 294.16M$ 172.13M$ 425.75M$ 1.25B
Currency in USD

Alnylam Pharma Earnings and Revenue History

Income Statement >

Alnylam Pharma Debt to Assets

Balance Sheet >

Alnylam Pharma Cash Flow

Cash Flow >

Alnylam Pharma Forecast EPS vs Actual EPS

Earnings >